NEXVIADYME

USDailyMed:Avalglucosidase alfa AU:B1 A16AB22(WHO) AU:S4(Prescription only)CA:℞-onlyUS:℞-onlyEU:Rx-only 1802558-87-7 DB16099 EO144CP0X9 D11744 Avalglucosidase alfa, sold under the brand nameNexviazyme, is anenzyme replacement therapymedication used for the treatment ofglycogen storage disease type II(Pompe disease). The most common side effects include headache, fatigue, diarrhea, nausea, joint pain (arthralgia), dizziness, muscle pain (myalgia), itching (pruritus), vomiting, difficulty breathing (dyspnea), skin redness (erythema), feeling of "pins and needles" (paresthesia) and skin welts (urticaria). Avalglucosidase alfa was approved for medical use in the United States in August 2021,and in the European Union in June 2022.